Analysis of acute-phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer

International Journal of Cancer

Volumn 131, Issue 4, 2012, Pages 911-923

  Dowling, Paul ^a   Clarke, Colin ^a   Hennessy, Kim ^a   Torralbo Lopez, Beatriz ^b   Ballot, Jo ^c   Crown, John ^c   Kiernan, Ingrid ^d   O'Byrne, Kenneth J ^d   Kennedy, M John ^d   Lynch, Vincent ^a   Clynes, Martin ^a  

^a DUBLIN CITY UNIVERSITY   (Ireland)

^b All Ireland Cooperative Oncology Research Group   (Ireland)

^c ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^d ST JAMES S HOSPITAL   (Ireland)

Author keywords

acute phase proteins; biomarkers; cancer; proteomics

Indexed keywords

BIOLOGICAL MARKER; CLUSTERIN; COMPLEMENT COMPONENT C3; FETUIN A; HAPTOGLOBIN; SERUM AMYLOID A;

ACCURACY; ADULT; AGED; ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER STAGING; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LEAVE ONE OUT CROSS VALIDATION; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ACUTE-PHASE PROTEINS; ADULT; AGED; AGED, 80 AND OVER; ALPHA-2-HS-GLYCOPROTEIN; BREAST NEOPLASMS; CLUSTERIN; COLORECTAL NEOPLASMS; COMPLEMENT C3; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HAPTOGLOBINS; HUMANS; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SERUM AMYLOID A PROTEIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84862538817     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26462     Document Type: Article

References (50)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer Statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Higa GM,. Breast cancer: beyond the cutting edge. Exp Opin Pharmacother 2009; 10: 2479-98.
3. Brooks DD, Wolf A, Smith RA, Dash C, Guessous I,. Prostate cancer screening 2010: updated recommendations from the American Cancer Society. J Natl Med Assoc 2010; 102: 423-9.
4. Simpson RJ, Bernhard OK, Greening DW, Moritz RL,. Proteomics-driven cancer biomarker discovery: looking to the future. Curr Opin Chem Biol 2008; 12: 72-7.
5. Boja E, Hiltke T, Rivers R, Kinsinger CR, Rahbar A, Mesri M, Rodriguez H,. The evolution of clinical proteomics and its role in medicine. J Proteome Res 2011; 10: 66-84.
6. Tu C, Rudnick PA, Martinez MA, Cheek KL, Stein SE, Slebos RJ, Liebler DC,. Depletion of abundant plasma proteins and limitations of plasma proteomics. J Proteome Res 2010; 9: 4982-91.
7. Wood SL, Rogers M, Cairns DA, Paul A, Thompson D, Vasudev NS, Selby PJ, Banks RE,. Association of serum amyloid A protein and peptide fragments with prognosis in renal cancer. Br J Cancer 2010; 103: 101-11.
8. Pang WW, Abdul-Rahman PS, Wan-Ibrahim WI, Hashim OH,. Can the acute-phase reactant proteins be used as cancer biomarkers? Int J Biol Markers 2010; 25: 1-11.
9. Cho WC, Yip TT, Yip C, Yip V, Thulasiraman V, Ngan RK, Yip TT, Lau WH, Au JS, Law SC, Cheng WW, Ma VW, et al. Identification of serum amyloid a protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clin Cancer Res 2004; 10: 43-52. (Pubitemid 38114160)
10. Miyake H, Muramaki M, Furukawa J, Kurahashi T, Fujisawa M,. Serum level of clusterin and its density in men with prostate cancer as novel biomarkers reflecting disease extension. Urology 2010; 75: 454-9.
11. Dowling P, O'Driscoll L, Meleady P, Henry M, Roy S, Ballot J, Moriarty M, Crown J, Clynes M,. 2-D difference gel electrophoresis of the lung squamous cell carcinoma versus normal sera demonstrates consistent alterations in the levels of ten specific proteins. Electrophoresis 2007; 28: 4302-10. (Pubitemid 350259032)
12. Petri AL, Simonsen AH, Hogdall E, Christensen IJ, Kjaer SK, Yip C, Risum S, Pedersen AT, Hartwell D, Fung ET, Hogdall C,. Comparison of proteomic biomarker panels in urine and serum for ovarian cancer diagnosis. Proteomics Clin Appl 4: 304-14.
13. Bitterlich N, Muley T, Schneider J,. Centre-independent detection of non-small cell lung cancer (NSCLC) by means of classification with receiver operating characteristic (ROC)-based data transformation. Anticancer Res 30: 1661-5.
14. Bloom GC, Eschrich S, Zhou JX, Coppola D, Yeatman TJ,. Elucidation of a protein signature discriminating six common types of adenocarcinoma. Int J Cancer 2007; 120: 769-75. (Pubitemid 46175395)
15. Ragazzi E, Pucciarelli S, Seraglia R, Molin L, Agostini M, Lise M, Traldi P, Nitti D,. Multivariate analysis approach to the plasma protein profile of patients with advanced colorectal cancer. J Mass Spectrom 2006; 41: 1546-53. (Pubitemid 46049744)
16. Hosmer D, Lemeshow S,. Applied logistic regression, Wiley Series in probability and statistics, 2nd edn., Wiley, 2000.
17. Kazama JJ,. What does the circulating AHSG/fetuin-A level tell us? Clin Exp Nephrol 2007; 11: 336-7. (Pubitemid 350277620)
18. Petersen NE, Elmgreen J, Teisner B, Svehag SE,. Activation of classical pathway complement in chronic inflammation. Elevated levels of circulating C3d and C4d split products in rheumatoid arthritis and Crohn's disease. Acta Med Scand 1988; 223: 557-60.
19. Nuutinen T, Suuronen T, Kauppinen A, Salminen A,. Clusterin: a forgotten player in Alzheimer's disease. Brain Res Rev 2009; 61: 89-104.
20. Quaye IK,. Haptoglobin, inflammation and disease. Trans R Soc Trop Med Hyg 2008; 102: 735-42.
21. dos Anjos BL, Grotto HZ,. Evaluation of C-reactive protein and serum amyloid A in the detection of inflammatory and infectious diseases in children. Clin Chem Lab Med 48: 493-9.
22. Hardardottir I, Kunitake ST, Moser AH, Doerrler WT, Rapp JH, Grunfeld C, Feingold KR,. Endotoxin and cytokines increase hepatic messenger RNA levels and serum concentrations of apolipoprotein J (clusterin) in Syrian hamsters. J Clin Invest 1994; 94: 1304-9. (Pubitemid 24286476)
23. Malle E, Sodin-Semrl S, Kovacevic A,. Serum amyloid A: an acute-phase protein involved in tumour pathogenesis. Cell Mol Life Sci 2009; 66: 9-26.
24. Ganapathi MK, Rzewnicki D, Samols D, Jiang SL, Kushner I,. Effect of combinations of cytokines and hormones on synthesis of serum amyloid A and C-reactive protein in Hep 3B cells. J Immunol 1991; 147: 1261-5.
25. Sakwe AM, Koumangoye R, Goodwin SJ, Ochieng J,. Fetuin-A (ahsg) is a major serum adhesive protein that mediates growth signaling in breast tumor cells. J Biol Chem.
26. Petrik V, Saadoun S, Loosemore A, Hobbs J, Opstad KS, Sheldon J, Tarelli E, Howe FA, Bell BA, Papadopoulos MC,. Serum alpha 2-HS glycoprotein predicts survival in patients with glioblastoma. Clin Chem 2008; 54: 713-22. (Pubitemid 351573704)
27. Qiu Y, Patwa TH, Xu L, Shedden K, Misek DE, Tuck M, Jin G, Ruffin MT, Turgeon DK, Synal S, Bresalier R, Marcon N, et al. Plasma glycoprotein profiling for colorectal cancer biomarker identification by lectin glycoarray and lectin blot. J Proteome Res 2008; 7: 1693-703.
28. Hanas JS, Hocker JR, Cheung JY, Larabee JL, Lerner MR, Lightfoot SA, Morgan DL, Denson KD, Prejeant KC, Gusev Y, Smith BJ, Hanas RJ, et al. Biomarker identification in human pancreatic cancer sera. Pancreas 2008; 36: 61-9.
29. Andersen CL, Schepeler T, Thorsen K, Birkenkamp-Demtroder K, Mansilla F, Aaltonen LA, Laurberg S, Orntoft TF,. Clusterin expression in normal mucosa and colorectal cancer. Mol Cell Proteomics 2007; 6: 1039-48. (Pubitemid 47019405)
30. Pucci S, Bonanno E, Sesti F, Mazzarelli P, Mauriello A, Ricci F, Zoccai GB, Rulli F, Galata G, Spagnoli LG,. Clusterin in stool: a new biomarker for colon cancer screening? Am J Gastroenterol 2009; 104: 2807-15.
31. Pucci S, Mazzarelli P, Nucci C, Ricci F, Spagnoli LG,. CLU "in and out": looking for a link. Adv Cancer Res 2009; 105: 93-113.
32. Mazzarelli P, Pucci S, Spagnoli LG,. CLU and colon cancer. The dual face of CLU: from normal to malignant phenotype. Adv Cancer Res 2009; 105: 45-61.
33. Scaltriti M, Brausi M, Amorosi A, Caporali A, D'Arca D, Astancolle S, Corti A, Bettuzzi S,. Clusterin (SGP-2, ApoJ) expression is downregulated in low- and high-grade human prostate cancer. Int J Cancer 2004; 108: 23-30. (Pubitemid 37444439)
34. Rauhala HE, Porkka KP, Saramaki OR, Tammela TL, Visakorpi T,. Clusterin is epigenetically regulated in prostate cancer. Int J Cancer 2008; 123: 1601-9.
35. July LV, Akbari M, Zellweger T, Jones EC, Goldenberg SL, Gleave ME,. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 2002; 50: 179-88. (Pubitemid 34137445)
36. Smeets MB, Fontijn J, Kavelaars A, Pasterkamp G, De Kleijn DP,. The acute phase protein haptoglobin is locally expressed in arthritic and oncological tissues. Int J Exp Pathol 2003; 84: 69-74. (Pubitemid 36754271)
37. Yoshioka M, Watanabe A, Shimada N, Murata H, Yokomizo Y, Nakajima Y,. Regulation of haptoglobin secretion by recombinant bovine cytokines in primary cultured bovine hepatocytes. Domest Anim Endocrinol 2002; 23: 425-33. (Pubitemid 35033453)
38. Shah A, Singh H, Sachdev V, Lee J, Yotsukura S, Salgia R, Bharti A,. Differential serum level of specific haptoglobin isoforms in small cell lung cancer. Curr Proteomics 7: 49-65.
39. Chen CB, Su YC, Huang TT, Ho HC, Chang YT, Tung YT, Lee WC,. Differentially expressed serum haptoglobin alpha chain isoforms with potential application for diagnosis of head and neck cancer. Clin Chim Acta 2008; 398: 48-52.
40. Hamrita B, Chahed K, Trimeche M, Guillier CL, Hammann P, Chaieb A, Korbi S, Chouchane L,. Proteomics-based identification of alpha1-antitrypsin and haptoglobin precursors as novel serum markers in infiltrating ductal breast carcinomas. Clin Chim Acta 2009; 404: 111-8.
41. Kumar DM, Thota B, Shinde SV, Prasanna KV, Hegde AS, Arivazhagan A, Chandramouli BA, Santosh V, Somasundaram K,. Proteomic identification of haptoglobin alpha2 as a glioblastoma serum biomarker: implications in cancer cell migration and tumor growth. J Proteome Res 9: 5557-67.
42. Gutfeld O, Prus D, Ackerman Z, Dishon S, Linke RP, Levin M, Urieli-Shoval S,. Expression of serum amyloid A, in normal, dysplastic, and neoplastic human colonic mucosa: implication for a role in colonic tumorigenesis. J Histochem Cytochem 2006; 54: 63-73. (Pubitemid 43049416)
43. Lau SH, Sham JS, Xie D, Tzang CH, Tang D, Ma N, Hu L, Wang Y, Wen JM, Xiao G, Zhang WM, Lau GK, et al. Clusterin plays an important role in hepatocellular carcinoma metastasis. Oncogene 2006; 25: 1242-50.
44. Hsu SJ, Nagase H, Balmain A,. Identification of Fetuin-B as a member of a cystatin-like gene family on mouse chromosome 16 with tumor suppressor activity. Genome 2004; 47: 931-46. (Pubitemid 40033906)
45. Pectasides D, Pavlidis N, Gogou L, Antoniou F, Nicolaides C, Tsikalakis D,. Clinical value of CA 15-3, mucin-like carcinoma-associated antigen, tumor polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patients. Am J Clin Oncol 1996; 19: 459-64. (Pubitemid 26314875)
46. Moertel CG, O'Fallon JR, Go VL, O'Connell MJ, Thynne GS,. The preoperative carcinoembryonic antigen test in the diagnosis, staging, and prognosis of colorectal cancer. Cancer 1986; 58: 603-10. (Pubitemid 16072059)
47. Molina R, Holdenrieder S, Auge JM, Schalhorn A, Hatz R, Stieber P,. Diagnostic relevance of circulating biomarkers in patients with lung cancer. Cancer Biomark 2010; 6: 163-78.
48. Molina R, Auge JM, Bosch X, Escudero JM, Vinolas N, Marrades R, Ramirez J, Carcereny E, Filella X,. Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology. Tumour Biol 2009; 30: 121-9.
49. Schroder FH,. PSA screening-a review of recent studies. Eur J Cancer 2009; 45 (Suppl 1): 402-4.
50. Hanash SM, Pitteri SJ, Faca VM,. Mining the plasma proteome for cancer biomarkers. Nature 2008; 452: 571-9. (Pubitemid 351483371)